Category: News

Coda Holdings Closes $147 Million Series D fundraising

Los Angeles, CA September 19, 2011 – CODA Holdings, a leading developer of all-electric vehicles and advanced battery systems, announced the successful completion of its

MEI PHARMA to acquire Pracinostat, a potential best-in-class HDAC inhibitor

San Diego – August 7, 2012 (tentative) – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for

Meygen Lodges Plans for Tidal Array

Tidal energy developer Meygen has lodged plans for the first phase of a 400 megawatt project in the Inner Sounds of the Pentland Firth.

Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push

Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push

Inviragen Aims to Continue Development of INV21

Hand, Foot and Mouth Disease (HFMD) is caused by enteroviral pathogens such as enterovirus 71 (EV71). Although this is generally a self-limiting disease characterised by fever, mouth ulcers,

Atlantis wins Singapore sustainability awards 2012

Atlantis Resources Corporation received an Achievement of Excellence award in the Small & Medium Enterprise Category at the 2012 Singapore Business Federation awards dinner ceremony held

Adamas Pharmaceuticals Presents Update on Nurelin Program at Cambridge Healthtech Institute’s Parkinson’s Conference

EMERYVILLE, CALIF., June 4, 2012 – Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its NurelinTM (amantadine

NewNet Investor Profile: Chu Swee Yeok, CEO EDBI

A strategic investor based in Singapore investing in globally competitive businesses in Smart Energy and Efficiency as well as Sustainable Environment.

Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda

EMERYVILLE, CALIF., May 15, 2012 – Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the

Cell Therapeutics Enters Into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis